BACKGROUND: Neurological soft signs (NSS) are hypothesized as candidate endophenotypes for schizophrenia, but their prevalence and relations with clinical and demographic data are unknown. The authors undertook a quantification (meta-analysis) of the published literature on NSS in patients with schizophrenia and healthy controls. A systematic search was conducted for published articles reporting NSS and related data using standard measures in schizophrenia and healthy comparison groups. METHOD: A systematic search was conducted for published articles reporting data on the prevalence of NSS in schizophrenia using standard clinical rating scales and healthy comparison groups. Meta-analyses were performed using the Comprehensive Meta-analysis software package. Effect sizes (Cohen d) indexing the difference between schizophrenic patients and the healthy controls were calculated on the basis of reported statistics. Potential moderator variables evaluated included age of patient samples, level of education, sample sex proportions, medication doses, and negative and positive symptoms. RESULTS: A total of 33 articles met inclusion criteria for the meta-analysis. A large and reliable group difference (Cohen d) indicated that, on average, a majority of patients (73%) perform outside the range of healthy subjects on aggregate NSS measures. Cognitive performance and positive and negative symptoms share 2%-10% of their variance with NSS. CONCLUSIONS: NSS occur in a majority of the schizophrenia patient population and are largely distinct from symptomatic and cognitive features of the illness.
BACKGROUND: Neurological soft signs (NSS) are hypothesized as candidate endophenotypes for schizophrenia, but their prevalence and relations with clinical and demographic data are unknown. The authors undertook a quantification (meta-analysis) of the published literature on NSS in patients with schizophrenia and healthy controls. A systematic search was conducted for published articles reporting NSS and related data using standard measures in schizophrenia and healthy comparison groups. METHOD: A systematic search was conducted for published articles reporting data on the prevalence of NSS in schizophrenia using standard clinical rating scales and healthy comparison groups. Meta-analyses were performed using the Comprehensive Meta-analysis software package. Effect sizes (Cohen d) indexing the difference between schizophrenicpatients and the healthy controls were calculated on the basis of reported statistics. Potential moderator variables evaluated included age of patient samples, level of education, sample sex proportions, medication doses, and negative and positive symptoms. RESULTS: A total of 33 articles met inclusion criteria for the meta-analysis. A large and reliable group difference (Cohen d) indicated that, on average, a majority of patients (73%) perform outside the range of healthy subjects on aggregate NSS measures. Cognitive performance and positive and negative symptoms share 2%-10% of their variance with NSS. CONCLUSIONS: NSS occur in a majority of the schizophreniapatient population and are largely distinct from symptomatic and cognitive features of the illness.
Authors: Richard D Sanders; Daniel Schuepbach; Gerald Goldstein; Gretchen L Haas; John A Sweeney; Matcheri S Keshavan Journal: J Neuropsychiatry Clin Neurosci Date: 2004 Impact factor: 2.198
Authors: Giuseppe Bersani; Simona Gherardelli; Roberta Clemente; Massimo Di Giannantonio; Alfredo Grilli; Chiara M V Conti; Michael S Exton; Pio Conti; Robert Doyle; Paolo Pancheri Journal: J Clin Psychopharmacol Date: 2005-08 Impact factor: 3.153
Authors: R D Sanders; M S Keshavan; S D Forman; J N Pieri; N McLaughlin; D N Allen; D P van Kammen; G Goldstein Journal: Psychiatry Res Date: 2000-09-11 Impact factor: 3.222
Authors: Dusan Hirjak; Philipp A Thomann; Robert C Wolf; Katharina M Kubera; Caspar Goch; Jan Hering; Klaus H Maier-Hein Journal: Hum Brain Mapp Date: 2017-04-21 Impact factor: 5.038
Authors: T Moberget; N T Doan; D Alnæs; T Kaufmann; A Córdova-Palomera; T V Lagerberg; J Diedrichsen; E Schwarz; M Zink; S Eisenacher; P Kirsch; E G Jönsson; H Fatouros-Bergman; L Flyckt; G Pergola; T Quarto; A Bertolino; D Barch; A Meyer-Lindenberg; I Agartz; O A Andreassen; L T Westlye Journal: Mol Psychiatry Date: 2017-05-16 Impact factor: 15.992
Authors: Olabisi Owoeye; Tara Kingston; Paul J Scully; Patrizia Baldwin; David Browne; Anthony Kinsella; Vincent Russell; Eadbhard O'Callaghan; John L Waddington Journal: Schizophr Bull Date: 2013-05-28 Impact factor: 9.306